ClinicalTrials.gg
RecruitingNCT05765695Updated Apr 16, 2024

Radiofrequency Ablation in TIR3A Nodules With Negative Genetic Evaluation

An interventional study of Radiofrequency ablation performed with a 19 gauge STARmed needle. in Thyroid Nodule, sponsored by Istituto Auxologico Italiano. Recruiting at 1 site in Italy. Per ClinicalTrials.gov, last updated 2024-04-16.

Sponsored by Istituto Auxologico Italiano · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Registered 2 years 1 month after the study started (first participant enrolled Jan 2021, registered Feb 2023).
  • Started Jan 2021; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Thyroid Nodule with a site in Italy — 6 open to participants now, 6 under way, none of them phase 3. Thyroid Nodule · Italy.

Started
2021
with 1 other
No phase
5 of 11
2 open now
Registered
6th of 11
by date
Lead sponsor
1 of 11
Istituto Auxologico Italiano

Among the 11 studies in Thyroid Nodule with a site in Italy, this one is one of 2 that started in 2021, is one of 5 with no phase, and was the 6th registered.

Thyroid Nodule

208 studies on the registry are indexed under Thyroid Nodule; 64 are open to participants now.

Browse Thyroid Nodule studies →

Open to participants now

6 of the 11 studies in Thyroid Nodule with a site in Italy are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 43 Thyroid Nodule studies recruiting now, 33 (77%) set no upper age limit and 5 (12%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Thyroid Nodule with a site in Italy, or all of them as a file.
02

Study summary

The goal of this clinical trial is to demonstrate that TIR3A nodules with negative genetic test can be safely and effectively treated by radiofrequency ablation, with nodular shrinkage and improvement of clinical symptoms.

Fine needle aspiration cytology is the gold standard test for differential diagnosis of thyroid nodules, but sometimes the result can be indeterminate with a risk of malignancy of 10-30%. In these cases the ablation is not indicated and many patients with benign nodules that may benefit from the procedure are not treated.

All the patients enrolled must have a TIR3A cytology and negative genetic test for mutations associated with thyroid carcinoma. Before the ablation blood, evaluation of serum TSH, anti-thyroglobulin antibodies, anti-thyroid peroxidase antibodies and calcitonin levels will be performed.

03

Conditions studied

  • Thyroid Nodule

Browse trials for

Keywords

  • thyroid nodule
  • indeterminate
  • genetic
  • radiofrequency ablation
  • follow-up
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with thyroid nodule eligible for radiofrequency ablation, with low-risk indeterminate lesion cytology (TIR3A) and negative genetic test for mutations associated with thyroid carcinoma

Exclusion criteria

Exclusion Criteria:

  • Patients who are not able to sign the
  • Patients with to radiofrequency ablation
  • Patients with cytology different from TIR3A
  • Patients with positive genetic test for mutations associated with thyroid carcinoma
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Treated group

    Procedure: Radiofrequency ablation performed with a 19 gauge STARmed needle.

Interventions

  • ProcedureRadiofrequency ablation performed with a 19 gauge STARmed needle.

    The ablation with radiofrequency is a safe and effective minimally invasive procedure that results in thermal tissue necrosis. A needle electrode is inserted into the thyroid nodule using ultrasound guidance and generates heat by alternating electric current causing thermal injury. Afterwards, the ablated tissue is gradually absorbed with progressive shrinkage of the nodule.

06

What researchers measure

Primary outcomes

  1. Thyroid nodule volume reduction rate

    The change rate of the thyroid nodule volume after radiofrequency ablation compared to baseline

    Time frame: 1 month after the procedure

  2. Thyroid nodule volume reduction rate

    The change rate of the thyroid nodule volume after radiofrequency ablation compared to baseline

    Time frame: 6 months after the procedure

  3. Thyroid nodule volume reduction rate

    The change rate of the thyroid nodule volume after radiofrequency ablation compared to baseline

    Time frame: 12 months after the procedure

  4. Complication rate

    Assessment of the complications of the procedure and over time

    Time frame: When the procedure is performed

  5. Complication rate

    Assessment of the complications of the procedure and over time

    Time frame: 1 month after the procedure

  6. Complication rate

    Assessment of the complications of the procedure and over time

    Time frame: 6 months after the procedure

  7. Complication rate

    Assessment of the complications of the procedure and over time

    Time frame: 12 months after the procedure

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Jan 2025, 48 months after the start.

Of 68 non-industry interventional studies with no phase under Thyroid Nodule, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 46. This study's planned 48 months is above that.

Counting every sponsor, half of 73 studies reached it within 30 months; a quarter within 14 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2023
First posted
Mar 13, 2023
StartActual
Jan 10, 2021
Primary completionEst.
Jan 10, 2025
CompletionEst.
Jan 10, 2025
Last update
Apr 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05765695
Responsible party
Sponsor
First posted
Mar 13, 2023
Start date
Jan 10, 2021
Primary completion
Jan 10, 2025 (estimated)
Completion
Jan 10, 2025 (estimated)
Last update
Apr 16, 2024

Study contacts

Laura Fugazzola
Contact
l.fugazzola@auxologico.it
+390261911 ext. 2727

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion